SUBSCRIBE
SUBSCRIBE

Search Results

175 Results
Type
Section
Tag
Date
Location
175 Results for "reneuron".
  • Policy
    ReNeuron Provides Program and Regulatory Approvals Update
    ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update on its cell-based therapy programs.
    June 17, 2020
     · 
    5 min read
  • ReNeuron Signs New Exosome Research Collaboration
    ReNeuron Group plc announced that it has signed a new research evaluation agreement with a major U.S. biotechnology company in connection with the use of the Company’s proprietary exosomes for the delivery of novel gene silencing therapeutics.
    June 25, 2020
     · 
    2 min read
  • Business
    ReNeuron Announces Exosome Research Collaboration
    ReNeuron Group plc announced that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company’s proprietary exosomes to deliver novel therapeutics.
    April 7, 2020
     · 
    3 min read
  • Deals
    ReNeuron Update Regarding COVID-19
    ReNeuron Group plc, a global leader in the development of cell-based therapeutics, provides the following update in light of the COVID-19 pandemic and the effect on the Company of U.K. and U.S. government measures to contain the spread of the disease..
    April 6, 2020
     · 
    3 min read
  • Drug Development
    ReNeuron Announces Further Positive Data in Retinal Clinical Trial
    ReNeuron Group plc (AIM:RENE), a global leader in the development of cell-based therapeutics, is pleased to announce further positive long-term data from the ongoing Phase 2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP)
    June 29, 2020
     · 
    5 min read
  • ReNeuron to Participate in the Jefferies 2019 Global Healthcare Conference
    ReNeuron Group plc announced that ReNeuron’s management team will participate in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 in New York City.
    May 31, 2019
     · 
    1 min read
  • Drug Development
    ReNeuron Announces Positive Long-term Data in Retinal Clinical Trial
    ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce positive long-term data from the ongoing Phase 1/2a clinical trial of its hRPC stem cell therapy candidate in retinitis pigmentosa (RP) and plans to expand the ongoing study.
    February 24, 2020
     · 
    4 min read
  • Drug Development
    ReNeuron Announces Publication of Positive Phase 2a Stroke Clinical Data
    ReNeuron Group plc, a global leader in the development of cell-based therapeutics, is pleased to announce the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase 2a clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke.
    February 18, 2020
     · 
    3 min read
  • Business
    ReNeuron Partners with Fosun Pharma in China
    ReNeuron to receive upfront, near term and estimated success-based milestone payments of £80.0 million (US$104.8 million) and double-digit royalties on sales
    April 9, 2019
     · 
    4 min read
  • Policy
    ReNeuron Expands Exosome IP Portfolio with Key Patent Grants
    ReNeuron Group plc, a UK-based global leader in the development of cell-based therapeutics, announced that it has expanded its intellectual property estate via the grant of a number of key patents covering its exosome technology platform.
    July 16, 2019
     · 
    2 min read